如今，癌癥癌癥已不再被視為絕癥，而是有“慢性病化”的發(fā)展趨勢，伴隨這一趨勢，腫瘤耐藥問題顯得越發(fā)重要。

Nowadays, cancer tends to be managed as a chronic illness instead of a life-threatening disease, and this highlights the importance of drug resistance issues observed in tumors.

耐藥性的產(chǎn)生可能是由于病人體內(nèi)本身存在對原有療法不敏感的腫瘤細胞群體經(jīng)治療篩選后得以幸存壯大，造成復(fù)發(fā)。也有可能是在治療過程中，伴隨基因組改變、表觀遺傳學(xué)調(diào)控、代謝及免疫調(diào)控等驅(qū)動因素作用，促使腫瘤細胞獲得對藥物療法的耐受能力，引起疾病進展。

Drug resistance of tumors refers to the phenomenon where tumor cells in the patient's body develop higher tolerability to the original therapy post a period of treatment, leading to a compromised therapeutic benefit and disease progression.

耐藥機制多種機制，包括通過調(diào)節(jié)細胞內(nèi)外代謝通路如流入（Influx）與外排(Efflux)通路的調(diào)節(jié)，限制藥物成分發(fā)揮作用產(chǎn)生耐藥。

There are various mechanisms of drug resistance, including efflux pump-mediated mechanisms of multidrug resistance (MDR) and efflux pump-independent drug resistance mechanisms.

耐藥性的產(chǎn)生可能是由于病人體內(nèi)本省存在對原有療法不敏感的腫瘤細胞群體經(jīng)治療篩選后得以幸存壯大，造成復(fù)發(fā)。也可能是在治療過程中，伴隨基因組改變、表觀遺傳學(xué)調(diào)控、代謝及免疫調(diào)控等驅(qū)動因素作用，促使腫瘤細胞獲得對藥物療法的耐受能力，引起疾病進展。

The development of resistance may be due to the presence of pre-existing tumor cell populations which are not responsive to the original treatment.These populations can survive from the treatment and proliferate,leading to recurrence.It is also possible that, during the treatment process, tumor cells acquire the resistance out of genomic alternation,epigenetic changes, metabolism and immune regulations,etc.

耐藥的發(fā)生具有普遍性和個性化特點，耐藥模型是用于研究耐藥機制和開發(fā)新型治療藥物與療法的重要臨床前研究工具。

The occurrence of drug resistance is both universal and individualized. Resistant models are important preclinical research tools for drug resistance mechanism study and development of novel therapeutic drugs or strategies.

在美迪西，我們采用藥物沖擊誘導(dǎo)的方式來開發(fā)耐藥模型。

In Medicilon, we can exploit drug exposure induction approach for drug resistant model development purpose.

美迪西腫瘤耐藥模型

美迪西腫瘤動物模型